


 Cite this: *Chem. Commun.*, 2024, 60, 1428

 Received 5th December 2023,  
 Accepted 2nd January 2024

DOI: 10.1039/d3cc05924c

rsc.li/chemcomm


# Co-factor prosthesis facilitates biosynthesis of azido-pseudaminic acid probes for use as glycosyltransferase reporters†

 Tessa Keenan,<sup>a</sup> Harriet S. Chidwick,<sup>a</sup> Matthew Best,<sup>a</sup> Emily K. P. Flack,<sup>ab</sup> Nicholas D. J. Yates,<sup>a</sup> Natasha E. Hatton,<sup>a</sup> Matthew E. Warnes<sup>a</sup> and Martin A. Fascione<sup>ib\*</sup>

Truncated thioester *N,S*-diacetylcysteamine (SNAc) was utilised as a co-factor mimic for PseH, an acetyl-coA dependent aminoglycoside *N*-acetyltransferase, in the biosynthesis of the bacterial sugar, pseudaminic acid. Additionally, an azido-SNAc analogue was used to smuggle *N7*-azide functionality into the pseudaminic acid backbone, facilitating its use as a reporter of pseudaminyltransferase activity.

5,7-Diacetyl pseudaminic acid (Pse5Ac7Ac, **1**) and its analogues are rare non-mammalian sugars belonging to the nonulosonic acid family, a group of nine-carbon  $\alpha$ -keto-acid sugars that are widely distributed in nature and found in diverse cell-surface glycoconjugates.<sup>1</sup> Pse glycans are particularly prevalent in pathogenic bacterial species, including *Campylobacter jejuni*,<sup>2</sup> *Helicobacter pylori*,<sup>3,4</sup> *Shigella boydii*,<sup>5</sup> *Aeromonas caviae* and multidrug resistant ESKAPE pathogens *Pseudomonas aeruginosa* and *Acinetobacter baumannii*.<sup>6–10</sup> They are also recognised as virulence factors and are essential for correct flagellar assembly and motility in some bacteria,<sup>2,4,11</sup> as well as playing a role in immune evasion.<sup>12</sup> There is therefore a vital need to understand the biosynthesis of Pse derivatives and how they are incorporated into cell-surface glycoconjugates. Although significant progress has been made in understanding the biosynthesis of CMP-Pse5Ac7Ac **7** (Fig. 1A), the nucleotide activated form of the parent sugar that is the substrate for glycosyltransferases (GTs), the discovery and characterisation of GT enzymes that catalyse the incorporation of the sugar into glycoconjugates,<sup>13</sup> termed “pseudaminyltransferases” (PseTs), has lagged behind. This area of research has been hampered by requirement for straightforward access to Pse-based chemical probes, as well as sensitive and straightforward methods to screen for PseT activity. Using metabolic glycan engineering, others have demonstrated

the ability to label Pse-containing glycans in bacteria using chemical synthesis to access an ester-protected *N5*-azidoacetamide-functionalised Pse analogue,<sup>14</sup> or a functionalised intermediate in the Pse biosynthetic pathway, 6-deoxy-*Alt*-NAC4NAz.<sup>15,16</sup> To be incorporated into the cell-surface glycans, these analogues would need to enter the Pse biosynthetic pathway *in vivo* to produce CMP nucleotide activated forms of the sugars, and then be processed by PseTs. In this study we therefore explored whether similarly azido functionalised Pse analogues could serve as bioorthogonal probes that would facilitate preliminary *in vitro* screening of enzymes for PseT activity, prior to time and resource intensive full characterisation of an enzyme and challenging scale up of the glycoside forming reaction.



**Fig. 1** (A) The biosynthetic pathway for CMP-Pse5Ac7Ac **7** reconstituted *in vitro*. (B) Crystal structure of *C. jejuni* PseH (PDB 4XPL)<sup>17</sup> in complex with its co-factor acetyl-CoA **8** (ball and stick model, carbon-bright green, oxygen-red, nitrogen-blue, sulfur-yellow, phosphorus-magenta) showing hydrogen bonds (black dotted lines) between residues (stick model, carbon-ice blue, oxygen-red, nitrogen-blue) and the pantetheine arm and pyrophosphate group. The acetyl group of **8** is highlighted in a red box. (C) Structural similarity between **8** and SNAc **9** (highlighted in blue). (D) PseH co-factor prosthesis with **9** and CoA.

<sup>a</sup> Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK.  
 E-mail: martin.fascione@york.ac.uk

<sup>b</sup> Department of Biology, University of York, York, YO10 5DD, UK

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3cc05924c>



In previous work we reconstituted a biosynthetic route for the synthesis of CMP-Pse5Ac7Ac **7** *in vitro*, starting from UDP-GlcNAc **2** and using enzymes from *C. jejuni* (PseBCHGI) and *A. caviae* (PseF) (Fig. 1A).<sup>18</sup> Additionally, we established a method for co-factor regeneration using PseH, the third enzyme in the biosynthetic pathway, demonstrating that the natural co-factor acetyl coenzyme-A (Ac-CoA, **8**) could be substituted for *S*-acetyl thiocholine iodide and coenzyme-A (CoA). PseH is an aminoglycoside *N*-acetyltransferase that catalyses acetyl transfer to C4 of UDP-4-amino-4,6-dideoxy- $\beta$ -*D*-AltNAc **4**, and part of the GNAT enzyme superfamily which utilise **8** as a co-factor.<sup>17,19</sup> It has been proposed that the reactivity of the acetyl transfer in these enzymes stems from the pantetheine arm, and is largely unaffected by the distal parts of the Ac-CoA structure.<sup>20</sup> This is evident in the crystal structure of *C. jejuni* PseH in complex with Ac-CoA, where three hydrogen bonds are formed between the pantetheine arm and the surrounding active site residues (Fig. 1B).<sup>17</sup> Interestingly, there are examples of CoA thioester utilising acetyltransferases that have shown promiscuity towards truncated thioesters such as *N,S*-diacetyl cysteamine (SNAc), facilitating the introduction of unnatural functionality, in an approach we denominate “co-factor prosthesis”.<sup>21–23</sup> Considering this precedent and the similarity of SNAc **9** to the pantetheine arm of **8** (Fig. 1C) and the positioning of the co-factor in the PseH active site (Fig. 1B), we hypothesised that SNAc **9** might serve as an alternative PseH co-factor (Fig. 1D) and enable us to smuggle unnatural functionality into Pse5Ac7Ac at the *N7* position, *via* our reconstituted biosynthetic pathway.

To investigate the utility of SNAc **9** in a co-factor prosthesis approach for PseH catalysed acetylation, small-scale reactions were assembled containing UDP-GlcNAc **2** (2 mM), PseB (5  $\mu$ M) and PseC (20  $\mu$ M), as well as their associated co-factors. Following PseBC product **4** formation, PseH (10  $\mu$ M), SNAc **9** (5 mM) and Co-A (0.3 mM) were added and the samples were analysed by negative ESI-LC-MS. A peak consistent with the mass of the acetylated PseH product **5** ( $[M - H]^-$  *m/z* 631) was observed in the reaction and absent from the no SNAc control (Fig. S1, ESI<sup>†</sup>), suggesting that **9** could indeed serve as a co-factor for PseH. The utility of **9** was further demonstrated in the one-pot biosynthesis of Pse5Ac7Ac **1** on a semi-preparative scale starting from UDP-GlcNAc **2** (65 mg) with enzymes from *C. jejuni* (PseBCHGI) and their associated co-factors. The use of SNAc **9** as a PseH co-factor facilitated the isolation of 27 mg of Pse5Ac7Ac **1** in a yield of 76%. Next, functionalised *N*-acetyl cysteamines SNAc-N<sub>3</sub> **10** and SNAc-Alk **11** were investigated in our *in vitro* biosynthetic pathway, as a route to accessing Pse5Ac7N<sub>3</sub> **12** and Pse5Ac7Alk **13** (Fig. 2). In preliminary experiments using SNAc-N<sub>3</sub> **10** in a one-pot biosynthesis starting from UDP-GlcNAc **2** with *C. jejuni* PseBCHGI and the associated co-factors, we observed PseBC product inhibition (data not shown). Therefore, the biosynthesis was split into two parts where PseBC reaction was allowed to proceed first to afford **4** and then PseHGI and the associated co-factors, including the functionalised SNACs, were added second (Fig. 2A). In reactions assembled with SNAc-N<sub>3</sub> **10**, a peak consistent with




Fig. 2 (A) Two-step *in vitro* biosynthesis of *N7*-functionalised Pse analogues. (B) Reaction-scale screening of SNAc-N<sub>3</sub> **10** and SNAc-Alk **11** shows that only **11** can be used as a co-factor prosthesis with PseH, facilitating the biosynthesis of Pse5Ac7N<sub>3</sub> **12** with PseBCHGI in two steps. (C) Pse5Ac7N<sub>3</sub> **12** conversion to CMP-Pse5Ac7N<sub>3</sub> **14** by *A. caviae* PseF, as validated by negative ESI-LC-MS. Base peak chromatogram (BPC) shown in black. Extracted ion chromatogram (EIC) for CMP-Pse5Ac7N<sub>3</sub> **14**  $[M - H]^-$  *m/z* 679 shown in blue.

the mass of the desired product, Pse5Ac7N<sub>3</sub> **12** ( $[M - H]^-$  *m/z* 374) was observed after analysis by negative ESI-LC-MS (Fig. 2B and Fig. S2a, ESI<sup>†</sup>). In contrast, no Pse5Ac7Alk **13** product was observed in reactions assembled with SNAc-Alk **11** (Fig. S2b, ESI<sup>†</sup>). Additionally, there was no evidence of the alkyne-functionalised PseH product ( $[M - H]^-$  *m/z* 641) suggesting that the biosynthesis had stalled at PseH. This may be attributed to the low solubility of SNAc-Alk **11** or a lack of conformational flexibility. Following the successful demonstration on a reaction scale that SNAc-N<sub>3</sub> **10** could be used in co-factor prosthesis in our reconstituted biosynthetic pathway, Pse5Ac7N<sub>3</sub> **12** was then synthesised on a semi-preparative scale starting from 21 mg of UDP-GlcNAc **2**. As in the small-scale reactions, the PseBC reaction was carried out first. While it was possible to perform the PseGHI reaction without purification of the PseBC product first, we found that it was difficult to achieve pure Pse5Ac7N<sub>3</sub> **12** using this strategy. Therefore, PseBC product **4** was first purified by Biogel P2 column chromatography and then converted to Pse5Ac7N<sub>3</sub> **12** using SNAc-N<sub>3</sub> **10**, PseGHI and the associated co-factors. Following a second Biogel P2 column purification, 3.9 mg of Pse5Ac7N<sub>3</sub> **12** was isolated in an overall yield of 33%. Next, we sought to demonstrate that Pse5Ac7N<sub>3</sub> **12** was a suitable substrate for *A. caviae* PseF, a CMP-Pse5Ac7Ac synthetase, for the formation of the activated glycosyl donor  $\alpha$ CMP-Pse5Ac7N<sub>3</sub> **14**.<sup>24</sup> Pse5Ac7N<sub>3</sub> **12** was incubated with PseF in the presence of cytidine triphosphate (CTP) and the formation of the desired crude product **14** was validated by negative ESI-LC-MS (Fig. 2C) and by NMR following treatment with alkaline phosphatase (Fig. S5 and S6a, ESI<sup>†</sup>). Notably, we observed some evidence of hydrolytic instability of **14**, as is a classic feature of many sugar nucleotides.<sup>25,26</sup> However, calculation of the difference in chemical shift between the H<sub>3ax</sub> and H<sub>3eq</sub> ( $\Delta$ ppm H<sub>3eq</sub>-H<sub>3ax</sub> = 0.62 ppm) validated the axially orientated *O*-CMP group (Fig. S5c, ESI<sup>†</sup>).<sup>27</sup> Having unequivocally confirmed turnover of **12** by PseF, we set out to demonstrate the utility of  $\alpha$ CMP-Pse5Ac7N<sub>3</sub> **14** as a bioorthogonal reporter of PseT activity (Fig. 3). To limit potential CMP-donor hydrolysis,






Fig. 3 Strategy for using Pse5Ac7N<sub>3</sub> **12** as a bioorthogonal reporter for PseT activity. Overlaid 545–565 nm chromatogram shows a peak eluting at 7.25 min in the reaction (black) that is absent from control reactions (red and blue). The mass spectrum under the peak shows an ion at the expected mass of the sulfo-Cy3-conjugated Pse5Ac7N<sub>3</sub>-LacNAc **17**  $[M - H]^-$   $m/z$  1406.5. Full chromatogram shown in Fig. S10 (ESI<sup>†</sup>). Note that the regio and stereochemistry of the glycosidic linkage to Pse5Ac7Az in trisaccharide **15** are omitted as they cannot be unambiguously assigned without full NMR characterisation, although sialyltransferase tPm0188Ph was previously demonstrated to afford Pse- $\beta$ 2,3-Gal linkages using  $\alpha$ CMP-Pse5Ac7Ac as a donor.<sup>24</sup>

in a proof of concept experiment we opted to use Pse5Ac7N<sub>3</sub> **12** in a one-pot reaction with both PseF and a sialyltransferase with PseT activity.

We selected the promiscuous inverting sialyltransferase (SiaT) from *Pasteurella multocida*, tPm0188Ph for this experiment, as it was previously shown to convert  $\alpha$ CMP-Pse5Ac7Ac **7** to  $\beta$ 2,3-linked Pse5Ac7Ac-terminated glycosides.<sup>24</sup> Therefore, Pse5Ac7N<sub>3</sub> **12** (1 mM) was first incubated with *A. caviae* PseF to allow the formation of  $\alpha$ CMP-Pse5Ac7N<sub>3</sub> **14**, as validated by negative ESI-LC-MS (Fig. S7, ESI<sup>†</sup>), before the addition of SiaT tPm0188Ph and LacNAc to drive the formation of the anticipated product, Pse5Ac7N<sub>3</sub>-LacNAc **15**. However, after 18 h, no evidence of the desired product **15** ( $[M - H]^-$   $m/z$  738) was observed (Fig. S8, ESI<sup>†</sup>), suggesting that either the SiaT tPm0188Ph could not use **14** as a substrate, or that the low-level formation of the Pse5Ac7N<sub>3</sub>-LacNAc **15** product could not be detected under the conditions of the reaction. To enable detection of low-level PseT activity we therefore used the azide-functionality in the Pse5Ac7N<sub>3</sub> moiety to label the reaction products with an alkyne functionalised fluorescent sulfo-cyanine 3 probe **16** using a copper-catalysed alkyne-azide cycloaddition (CuAAC) reaction. We anticipated that bioconjugation to **16** would facilitate the detection of our reaction products by both LC-MS and absorbance at 545–565 nm. Following analysis of the reactions by negative ESI-LC-MS, we observed a clear peak in the UV/Vis chromatogram with a retention time of 7.25 min, that was not present in the no SiaT and no LacNAc control reactions (Fig. 3 and Fig. S9, ESI<sup>†</sup>). Additionally, the average mass spectrum under the peak showed an ion at  $m/z$  1406.56, which is consistent with the

expected  $[M - H]^-$  for the sulfo-Cy3-conjugated Pse5Ac7N<sub>3</sub>-LacNAc product **17** at 1407.5 Da. These results demonstrate that sulfo-Cy3 labelling of Pse5Ac7N<sub>3</sub>-LacNAc **15** also aids the detection of the glycoside by negative ion LC-MS, showcasing the potential of Pse5Ac7N<sub>3</sub> **12** as a probe to screen for PseT activity.

In summary, we have shown that the truncated thioester SNAC **9** can serve as a co-factor for PseH in our reconstituted Pse biosynthetic pathway, enabling the facile, one-pot synthesis of Pse5Ac7Ac **1**. Additionally, we have demonstrated that SNAC-N<sub>3</sub> **9** can be used in an *in vitro* co-factor prosthesis strategy with PseH, enabling N7-azide functionality to be smuggled into the Pse backbone. In contrast, SNAC-Alk **11** was not a suitable PseH substrate and therefore could not facilitate the introduction of alkyne functionality into Pse. Grimes and colleagues previously demonstrated the introduction of alkyne functionality into N-acetylglucosamine in peptidoglycan using an elongated alkyne-functionalised SNAC.<sup>22</sup> It is therefore possible that similar use of a more conformationally flexible SNAC-Alk probe might enable turnover by PseH and subsequently facilitate the introduction of an alkyne functionality into the Pse backbone. Finally, we demonstrated the utility of Pse5Ac7N<sub>3</sub> **12**, in combination with *A. caviae* PseF activation, as a bioorthogonal reporter of PseT activity. We therefore anticipate this methodology will facilitate the discovery and validation of new *bona fide* PseTs.

TK, HC, MB, EF, NY, NH and MW performed the experiments and analysed the data. MAF designed the study and supervised the project. TK, HC and MAF wrote the manuscript.

We thank Dr Ed Bergstrom and The York Centre of Excellence in Mass Spectrometry. The York Centre of Excellence in



Mass Spectrometry was created thanks to a major capital investment through Science City York, supported by Yorkshire Forward with funds from the Northern Way Initiative, and subsequent support from EPSRC (EP/K039660/1; EP/M028127/1). This work was supported by The University of York, the EPSRC (PhD award to E. K. F. P.), the Rosetrees Trust (PhD award to H. C.), and a Horizon Europe Guarantee Consolidator award to M. A. F. (selected by the ERC, funded by UKRI; EP/X023680/1).

## Conflicts of interest

There are no conflicts to declare.

## References

- 1 A. L. Lewis, X. Chen, R. L. Schnaar and A. Varki, in *Essentials of Glycobiology*, ed. A. Varki, R. D. Cummings, J. D. Esko, P. Stanley, G. W. Hart, M. Aebi, D. Mohnen, T. Kinoshita, N. H. Packer, J. H. Prestegard, R. L. Schnaar and P. H. Seeberger, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY), 4th edn, 2022.
- 2 P. Thibault, S. M. Logan, J. F. Kelly, J.-R. Brisson, C. P. Ewing and P. Guerry, *J. Biol. Chem.*, 2001, **276**, 34862–34870.
- 3 A. I. M. Salah Ud-Din and A. Roujeinikova, *Cell. Mol. Life Sci.*, 2018, **75**, 1163–1178.
- 4 M. Schirm, E. Soo, A. Aubry, J. Austin, P. Thibault and S. Logan, *Mol. Microbiol.*, 2003, **48**, 1579–1592.
- 5 Y. A. Knirel, E. V. Vinogradov, V. L. L'vov, N. A. Kocharova, A. S. Shashkov, B. A. Dmitriev and N. K. Kochetkov, *Carbohydr. Res.*, 1984, **133**, C5–C8.
- 6 S. M. B. Tabei, P. G. Hitchen, M. J. Day-Williams, S. Merino, R. Vart, P.-C. Pang, G. J. Horsburgh, S. Viches, M. Wilhelms and J. M. Tomás, *J. Bacteriol.*, 2009, **191**, 2851–2863.
- 7 Y. A. Knirel, E. V. Vinogradov, A. S. Shashkov, B. A. Dmitriev, N. K. Kochetkov, E. S. Stanislavsky and G. M. Mashilova, *Eur. J. Biochem.*, 1987, **163**, 627–637.
- 8 N. Kocharova, A. Shashkov, B. Dmitriev and N. Kochetkov, *Bioorg. Khim.*, 1986, **12**, 1384–1390.
- 9 N. S. Sof'ya, A. V. Popova, A. S. Shashkov, M. M. Shneider, Z. Mei, N. P. Arbatsky, B. Liu, K. A. Miroshnikov, N. V. Volozhantsev and Y. A. Knirel, *Carbohydr. Res.*, 2015, **407**, 154–157.
- 10 J. J. Kenyon, A. M. Marzaioli, R. M. Hall and C. De Castro, *Glycobiology*, 2014, **24**, 554–563.
- 11 J. L. Parker, M. J. Day-Williams, J. M. Tomas, G. P. Stafford and J. G. Shaw, *MicrobiologyOpen*, 2012, **1**, 149–160.
- 12 H. N. Stephenson, D. C. Mills, H. Jones, E. Milioris, A. Copland, N. Dorrell, B. W. Wren, P. R. Crocker, D. Escors and M. Bajaj-Elliott, *J. Infect. Dis.*, 2014, **210**, 1487–1498.
- 13 H. S. Chidwick and M. A. Fascione, *Org. Biomol. Chem.*, 2020, **18**, 799–809.
- 14 A. M. Vibhute, H. Tamai, D. Logviniuk, P. G. Jones, M. Fridman and D. B. Werz, *Chem. – Eur. J.*, 2021, **27**, 10595–10600.
- 15 F. Liu, A. J. Aubry, I. C. Schoenhofen, S. M. Logan and M. E. Tanner, *ChemBioChem*, 2009, **10**, 1317–1320.
- 16 G. Andolina, R. Wei, H. Liu, Q. Zhang, X. Yang, H. Cao, S. Chen, A. Yan, X. D. Li and X. Li, *ACS Chem. Biol.*, 2018, **13**, 3030–3037.
- 17 W. S. Song, M. S. Nam, B. Namgung and S.-I. Yoon, *Biochem. Biophys. Res. Commun.*, 2015, **458**, 843–848.
- 18 H. S. Chidwick, E. K. Flack, T. Keenan, J. Walton, G. H. Thomas and M. A. Fascione, *Sci. Rep.*, 2021, **11**, 4756.
- 19 I. C. Schoenhofen, D. J. McNally, J.-R. Brisson and S. M. Logan, *Glycobiology*, 2006, **16**, 8C–14C.
- 20 Y. Modis and R. Wierenga, *Structure*, 1998, **6**, 1345–1350.
- 21 R. M. Mizanur, F. A. Jaipuri and N. L. Pohl, *J. Am. Chem. Soc.*, 2005, **127**, 836–837.
- 22 Y. Wang, K. M. Lazor, K. E. DeMeester, H. Liang, T. K. Heiss and C. L. Grimes, *J. Am. Chem. Soc.*, 2017, **139**, 13596–13599.
- 23 X. Xie, K. Watanabe, W. A. Wojcicki, C. C. Wang and Y. Tang, *Chem. Biol.*, 2006, **13**, 1161–1169.
- 24 E. K. Flack, H. S. Chidwick, G. Guchhait, T. Keenan, D. Budhadev, K. Huang, P. Both, J. Mas Pons, H. Ledru and S. Rui, *ACS Catal.*, 2020, **10**, 9986–9993.
- 25 C.-H. Lin, B. W. Murray, I. R. Ollmann and C.-H. Wong, *Biochemistry*, 1997, **36**, 780–785.
- 26 G. K. Wagner, T. Pesnot and R. A. Field, *Nat. Prod. Rep.*, 2009, **26**, 1172–1194.
- 27 Y. A. Knirel, E. T. Rietschel, R. Marre and U. Zahringer, *Eur. J. Biochem.*, 1994, **221**, 239–245.

